Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
US7550147B2 · kind B2 · utility
36Cited by
2References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 14, 2003 |
| Grant date | Jun 23, 2009 |
| Priority date | — |
| Expiry date | Mar 27, 2024 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into said new insertion site as medicine or vaccine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.